Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | IDH1 | O75874 | 2/20 | 0.34 |
| ▸ | FNTA | P49354 | 7/20 | 0.33 |
| ▸ | FNTB | P49356 | 7/20 | 0.33 |
| ▸ | FAAH | O00519 | 4/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12975874 | 0.86 | CYP2C19 (0.39) | IDH1FNTAFNTBKDM4ECYP2C19 | |
| SCHEMBL2883261 | 0.81 | OPRL1 (0.39) | OPRL1KCNH2FNTAFNTB | |
| SCHEMBL2877878 | 0.81 | OPRL1 (0.39) | OPRL1KCNH2FNTAFNTB | |
| SCHEMBL2147997 | 0.78 | CYP2D6 (0.37) | — | |
| SCHEMBL12975879 | 0.77 | OPRL1 (0.37) | OPRL1KCNH2 | |
| SCHEMBL12975917 | 0.77 | CYP2C19 (0.39) | FNTAFNTBKDM4ECYP2C19 | |
| SCHEMBL13000046 | 0.75 | OPRL1 (0.36) | OPRL1KCNH2 | |
| SCHEMBL2877588 | 0.75 | OPRL1 (0.49) | OPRL1KCNH2FAAHTRPV1KDM4E | |
| SCHEMBL2877407 | 0.74 | OPRL1 (0.43) | OPRL1KCNH2FNTAFNTB | |
| SCHEMBL2877409 | 0.74 | OPRL1 (0.43) | OPRL1KCNH2FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855294-B2 | Cycloalkanopyridine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-20070191419-A1 | Cycloalkanopyridine derivative | MSD K.K. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1726590-A1 | CYCLOALKANOPYRIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191419-A1 | Cycloalkanopyridine derivative | OPRL1, OPRK1, AVPR2 | OPRL1 1/4885KCNH2 969/4885IDH1 3596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.